Tag Archives: Pharmaceuticals

Nationwide Track and Trace System is Urgently Needed

Jim Greenwood

Today’s pharmaceutical distribution supply chain is governed largely by a patchwork of state laws and regulations that allows criminals to enter markets with the lowest safety requirements to inject counterfeit, unsafe, and potentially lethal products into the national supply chain. The state-by-state system is both onerous and ineffective, and the risk it poses to public health from counterfeiters can no longer be ignored. In a recent opinion piece for Roll Call, I write that: “Congress Read More >

Jim's Corner  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

2012 BIO Investor Forum: Discovery Track Snapshot

cablecar

BIO’s 11th Annual BIO Investor Forum is just around the corner – it will be held October 9-10, 2012 at the Palace Hotel in San Francisco, CA. The forum, or BIF as we call it around here, is an international investor event which explores trends and opportunities in life sciences. Broadly speaking, the focus is on venture-stage growth and emerging public companies. BIO’s Alan Eisenberg said it best earlier this week: “The aim of the Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

BioManufacturers Increasing Budgets for New Technologies

Eric Langer

By Eric Langer, Managing Partner, BioPlan Associates, Inc. Two-thirds Spending more for Improved Productivity Almost two-thirds (64.2 percent) of biomanufacturers will increase their budgets for new technologies to improve efficiencies and costs for downstream production this year. Data from our newly released 9th Annual Report and Survey of Biopharmaceutical Manufacturers, include responses from 302 global biomanufacturers, and an additional 185 vendors to the industry. We find that budget increases this year are not just incremental Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

Data Protection, Trans Pacific Partnership, and the US-Jordan FTA (Post 2 of 2)

Meeting

This post is a continuation of a previous post: Data Protection, the Trans Pacific Partnership, and the US-Jordan FTA (Post 1 of 2). 4.  Oxfam criticizes pharmaceutical innovators for not making all of their innovative drugs available in Jordan. Ryan responds: a.  Innovator companies introduced few new drugs before IP reform because local companies were using their know-how and clinical data to get marketing approval and brochures describing the drug’s therapeutic function and side effects Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Biotech IPO Update for May 18th, 2011

There are now eight biotech IPOs for 2011, bringing the total for the recent US IPO window to 28. Post-IPO performance is finally picking up with the median return at +14% for these 28 IPOs. Advanced BioHealing was scheduled to IPO this week, but Shire (SHGPY) came in with a $750M offer to buy the company. Sagent Pharmaceuticals (SGNT) was the most recent IPO, back in April. Sagent is a specialty pharma company selling injectable Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,